Clinical Trials match your criteria
-
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis
-
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) (ACE-Breast03)
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens
-
Randomized Phase 3 trial of IO102-IO103 (IDO-PD-L1) dual-antigen immunotherapeutic plus pembrolizumab versus pembrolizumab alone in unresectable or metastatic (advanced) melanoma
An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma.
-
Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors
-
Registry for Radiation Therapy
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy
-
Retrospective Evaluation of Intensity Modulated Electron Therapy in the Treatment of Patients with Radiation Therapy
Retrospective Evaluation of Intensity Modulated Electron Therapy in the Treatment of Patients with Radiation Therapy
-
Ph2, DS8201a w/wo Anastrozole for HER2 low hormone receptor positive
A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of trastuzumab deruxtecan (DS-8201a) with or without anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting
-
Treatment Planning Analysis for Painful Bone Metastases Radiother
Treatment Planning Analysis for Painful Bone Metastases Radiotherapy
-
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
